Trials / Recruiting
RecruitingNCT06522737
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- SecuraBio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duvelisib | oral capsules |
| DRUG | Gemcitabine | solution for intravenous infusion |
| DRUG | Bendamustine | solution for intravenous infusion |
Timeline
- Start date
- 2025-05-19
- Primary completion
- 2028-02-01
- Completion
- 2028-12-01
- First posted
- 2024-07-26
- Last updated
- 2026-04-06
Locations
44 sites across 10 countries: Belgium, Czechia, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06522737. Inclusion in this directory is not an endorsement.